Vanguard Group Inc. Has $21.18 Million Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Vanguard Group Inc. lessened its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 1.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,364,314 shares of the company’s stock after selling 24,427 shares during the quarter. Vanguard Group Inc. owned 3.85% of Dyne Therapeutics worth $21,184,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Citigroup Inc. increased its holdings in Dyne Therapeutics by 22.8% during the 3rd quarter. Citigroup Inc. now owns 61,895 shares of the company’s stock worth $555,000 after purchasing an additional 11,508 shares in the last quarter. Wellington Management Group LLP increased its holdings in Dyne Therapeutics by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 115,935 shares of the company’s stock worth $1,039,000 after purchasing an additional 5,371 shares in the last quarter. American Century Companies Inc. increased its holdings in Dyne Therapeutics by 36.9% during the 3rd quarter. American Century Companies Inc. now owns 27,407 shares of the company’s stock worth $246,000 after purchasing an additional 7,389 shares in the last quarter. Deutsche Bank AG increased its holdings in Dyne Therapeutics by 23.2% during the 3rd quarter. Deutsche Bank AG now owns 21,423 shares of the company’s stock worth $192,000 after purchasing an additional 4,031 shares in the last quarter. Finally, Walleye Trading LLC bought a new position in Dyne Therapeutics during the 3rd quarter worth about $218,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $25.85 on Friday. Dyne Therapeutics, Inc. has a 52 week low of $6.40 and a 52 week high of $30.27. The stock has a market capitalization of $2.23 billion, a P/E ratio of -6.56 and a beta of 0.95. The stock has a 50-day simple moving average of $25.78 and a 200 day simple moving average of $16.77.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.17). Research analysts forecast that Dyne Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now directly owns 151,590 shares in the company, valued at $3,895,863. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Richard William Scalzo sold 13,000 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $24.34, for a total value of $316,420.00. Following the completion of the sale, the senior vice president now directly owns 124,228 shares in the company, valued at $3,023,709.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Wildon Farwell sold 1,585 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the sale, the insider now owns 151,590 shares of the company’s stock, valued at $3,895,863. The disclosure for this sale can be found here. Insiders sold 1,888,532 shares of company stock worth $44,687,450 over the last three months. Insiders own 32.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DYN. Oppenheimer reiterated an “outperform” rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Tuesday, March 26th. Piper Sandler raised their price objective on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Stifel Nicolaus raised their price objective on Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. StockNews.com upgraded Dyne Therapeutics to a “sell” rating in a report on Thursday, December 21st. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.43.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.